【International Live Webinar Series】Strategies for Applying Clinical Trials in Europe歐洲臨床試驗申請策略與佈局
🌍此次學苑特別推出國際線上同步遠距課程,並與德國講師合作,提供學員最新的國際臨床試驗實務課程!
此次課程為系列課程,首堂為”歐洲臨床試驗申請策略與佈局”。對於想往歐洲發展、合作或與歐洲從事臨床試驗的相關公司廠商有很大的幫助!
Date:
Part 1: 2020/12/01 (Tues) 16:30 ~ 18:00 (GMT+8)
Part 2: 2020/12/03 (Thurs) 16:30 ~ 18:00 (GMT+8)
Location:Online Webinar Training
Instructor:Anika Staack, Founder of ARC-TRAICOA / EU-QPPV
【Course Outline】
Part 1 2020/12/01 (Tues) 16:30 ~ 18:00 (GMT+8)
A. Europe – One Union with differences
B. European Clinical Trial Directive
1.Role of national competent authorities
2.Role of ethics committees (central / local)
3.Role of investigator
4.Role of sponsor
5.Role of EMA
C. Planning clinical trials in Europe
1.Analysis of product
a.Indication
b.Patient group
2.Analysis of end points
3 .Analysis of protocol
4.Preparing feasibility
5.Choosing Key Opinion Leaders
6.Sponsor or IIT?
7.Similar studies already running?
Part 2 2020/12/03 (Thurs) 16:30 ~ 18:00 (GMT+8)
A. Applying clinical trial
1.Collecting information you need
2.Establishing study team
B. Required entry into EudraCT
C. Required approval from national HAs and ethics
D. Required fulfilment of national data protection laws
E. Considerations
1.Doing it by yourselves
2.Contracting CRO
3.Auditing
F. Upcoming issues: Site and patient recruitment, site resources, patients withdrawal, protocol amendments
G. Final presentation of study reports
Online Course Fees include 2 Webinars, 90 minutes each:
Special Price $160 USD per Person; Original Price $180 USD
(*1) Certificate of Attendance will be issued only if participants attend both part 1 & 2 webinar
(*2) Certificate of Completed Assessment will be issued only if participant pass the assessment
Register here 👉 https://forms.gle/Kj9yMVynsq7yzSzs8
Organizer:ARC-TRAICOA
Co-Organizer:Salt and Light Institute
【Target Audience】
(1.) Anyone who is interested in clinical trials in Europe
(2.) Anyone who has experience in working in clinical trials related field such as PI,PM,RA,RD,MA,DM,ST,CRA, CRC,QC,QA, etc)
【Instructor CV】
Anika Staack
Current Position:
Founder of ARC-TRAICOA
EU-Qualified Person for Pharmacovigilance (EU-QPPV)
Local German QPPV Consultant and Speaker
Previous Experience:
EU-QPPV / Stufenplanbeauftragte & Group Leader PV at Medice
Senior Drug Safety Manager at ICON
Lead Site Management Associate at PRA
Clinical Research Associate at SKM Oncology
Expertise:
Expertise Databases: European Medicine Agency EudraVigilance and xEVMPD
Quality Assurance: Audits & Inspections, SOP Writing and QA documentation, recalls and product quality
Clinical Trial Management: Feasibility, monitoring, eCRF set-up, database reconciliation, site selection, contract management, patient recruitment, study reports
Authorization process: PSMF, RMP & PSUR Writing, answering authority requests, Risk Management, overseeing product life-cycle
Education Background:
Master of Science (Biology)
Email: bioschool@biotech-edu.com Tel: (+886) 02-2545-9721 ext.18
ema drug 在 台灣光鹽生物科技學苑 Facebook 的精選貼文
✨✨光鹽開辦國際合作線上同步遠距研討會 (Live Webinar) - Anika Staack 講師介紹✨✨
🎉台灣光鹽生技學苑國際合作組伍亮霓召集人引薦了多位歐洲的產業專家擔任講師,首先學苑很榮幸地在此宣布 我們與德國醫藥顧問公司ARC-Traicoa UG (haftungsbeschränkt) 正式合作辦理國際線上同步遠距研討會(Live Webinar) 💻
我們的主講者,Anika Staack老師👩,在EMA及歐洲各國從事臨床試驗領域已有16年餘載的經驗,且身為EU-QPPV的一員,更是醫藥品申請NDA前及上市後不可或缺的角色。希望學員有機會一同參與線上課程,感受國際交流第一手資訊的悸動!💕
Anika也很親切、熱心地提供了她的一段自我介紹及影片,希望各位能在線上同步遠距研討會(Live Webinar)中與她互動:
“Greetings! My name is Anika Staack. I have more than 16 years of experience in the field of clinical trials and post-marketing of medicinal products. In the past, I had worked as CRA, Trial Site Manager, and Drug Safety Manager for global clinical trials of various indications and patient age groups. For several years now, I have been working as an EU-Qualified Person for Pharmacovigilance (EU-QPPV), overseeing product lifecycle of medicinal products, supplementals, and medical devices. Additionally, I have expertise in a wide array of clinical trial activities, ranging from audit and inspections, Quality Assurance, Regulatory Affairs, Manufacturing, to Marketing. I am knowledgeable about several databases and European pharmaceutical laws and regulations. Moreover, I have been providing training for FORUM Institute about Audits and Inspections and Risk Management. I am thrilled to meet you all in my webinar sessions. See you then!” ✨✨
ema drug 在 王姿允醫師。我的無齡秘笈。 Facebook 的精選貼文
[非類固醇消炎藥會惡化冠狀病毒感染??]
非類固醇消炎藥(non-steroid Anti-inflammatory drug,NSAID)有許多不同的商品名,常用於止痛消炎,效果迅速。
但歐洲藥品管理局 (European Medicines Agency)在昨天⚠️引起了關於使用NSAID(例如Ibuprofen)是否會加重冠狀病毒病(COVID-19)的疑問。
其實我並不意外,因為NSAID在過去研究發現確實會影響腸道菌相,在2019年一篇研究發現,使用NSAID惡化困難梭狀桿菌感染(Clostridium difficile infection )的文章,機轉應該就是改變了菌相造成發炎反應的失序。所以比較大型而嚴謹的腸道菌人體研究,在排除條件(exclusion criteria)中都會註明至少停用NSAID兩個月後,才能開始進入研究。
過去也有發現感染水痘帶狀皰疹病毒或是某些細菌感染的人,用了NSAID後會惡化病情的例子。NSAID這個藥的副作用之多,遍及心肝腎皮膚胃腸,也是容易過敏藥物前幾名的,會有這麼多莫名的副作用,對身體正常腸道菌的干擾自是不言可喻。
雖然還需更多的研究證實,不過老話一句,藥物請用在刀口上,會影響腸道菌的藥物不勝枚舉,不可不慎,應權衡利弊得失、確定益處大於害處時,方才使用。若在緩解症狀同時讓支持免疫系統的好菌被破壞殆盡,可說是因小失大,得不償失。
#不然也可能藥到命除
#沒有人是吃藥越吃越健康的
#一切違反自然的東西對腸道微生物可能都是浩劫
1. Maseda D, Zackular JP, Trindade B, et al. Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response. mBio. 2019;10(1):e02282-18. Published 2019 Jan 8. doi:10.1128/mBio.02282-18
新聞連結:
https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19
ema drug 在 European Medicines Agency - YouTube 的推薦與評價
Video content published by the European Medicines Agency. ... EU new rules for veterinary medicines and the actions EMA is taking to fight the superbugs. ... <看更多>